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ABSTRACT
Aberrant activation of Hedgehog (Hh) signaling is causative of BCCs and has been 
associated with a fraction of SCCs. Desmoglein 2 (Dsg2) is an adhesion protein that 
is upregulated in many cancers and overexpression of Dsg2 in the epidermis renders 
mice more susceptible to squamous-derived neoplasia. Here we examined a potential 
crosstalk between Dsg2 and Hh signaling in skin tumorigenesis. Our findings show 
that Dsg2 modulates Gli1 expression, in vitro and in vivo. Ectopic expression of Dsg2 
on Ptc1+/lacZ background enhanced epidermal proliferation and interfollicular activation 
of the Hh pathway. Furthermore, in response to DMBA/TPA, the Dsg2/Ptc1+/lacZ mice 
developed squamous lessons earlier than the WT, Ptc1+/lacZ, and Inv-Dsg2 littermates. 
Additionally, DMBA/TPA induced BCC formation in all mice harboring the Ptc1+/lacZ 
gene and the presence of Dsg2 in Dsg2/Ptc1+/lacZ mice doubled the BCC tumor burden. 
Reporter analysis revealed activation of the Hh pathway in the BCC tumors. However, 
in the SCCs we observed Hh activity only in the underlying dermis of the tumors. 
Furthermore, Dsg2/Ptc1+/lacZ mice demonstrated enhanced MEK/Erk1/2 activation 
within the tumors and expression of Shh in the dermis. In summary, our results 
demonstrate that Dsg2 modulates Hh signaling, and this synergy may accelerate skin 
tumor development by different mechanisms.
INTRODUCTION
Desmosomes are multi-protein, cell-cell adhesion 
complexes critical for tissue integrity and function [1, 2]. 
Desmoglein 2 (Dsg2), the most ubiquitously expressed 
desmosomal cadherin, is found in all simple epithelia 
and select non-epithelial cells such as cardiomyocytes 
[3–5]. In the skin, Dsg2 is highly expressed in the hair 
follicles but is found only at a low level in the basal layer 
of the interfollicular epidermis [6]. The role of Dsg2 
in tumorigenesis emerged with the findings that Dsg2 
expression is highly upregulated in several epithelial-
derived malignancies including basal cell carcinomas 
(BCC) and squamous cell carcinomas (SCC) [6]. 
Furthermore, we recently reported that ectopic expression 
of Dsg2 in the superficial epidermis renders mice more 
susceptible to tumor development [7].
The role of desmogleins in cell-cell adhesion has 
been well established [9]. However, recent work has 
recognized additional functions of desmogleins beyond 
the desmosomes. We previously demonstrated that 
Dsg2 enhances keratinocyte proliferation and survival, 
and activates mitogenic signaling cascades, including 
the MEK/Erk, PI3K/Akt and JAK/Stat3 pathways [7]. 
Furthermore, we established that Dsg2 interacts 
with caveolin-1, a key regulator of cell signaling [8]. 
Additionally, knockdown of Dsg2 in colon cancer cells 
inhibits proliferation by suppressing EGFR signaling [9]. 
Oncotarget2www.impactjournals.com/oncotarget
Taken together, these data support the notion that Dsg2 
may influence cancer development and progression, in part 
by regulating key signaling pathways that maintain skin 
homeostasis.
The Hedgehog (Hh) signaling pathway is another 
crucial regulator of skin homeostasis. Aberrant activation 
of the pathway in the skin is the causative factor of BCC, 
both sporadic and familiar [12]. The hallmark of canonical 
activity is the activation of the Gli family of transcription 
factors [13]. Gli activation is negatively regulated by the 
tumor suppressor Patched 1 (Ptc1). In the absence of the 
Hh ligands, Sonic (Shh), Indian (Ihh) or Desert (Dhh) Hh, 
Ptc1 inhibits Smoothened (Smo), leading to processing 
of Gli2 and Gli3 to their repressor forms, which blocks 
target gene transcription. The Hh pathway is activated 
upon binding of a Hh ligand to Ptc1, which leads to 
derepression of Smo and activation of the Gli transcription 
factors. Importantly, both Gli1 and Ptc1 are targets of Gli 
transcription and serve as readouts of the Hh pathway.
In the normal skin, Hh signaling is high during 
specific stages of the hair follicle cycle, but undetectable 
in the interfollicular epidermis [14]. However, the Hh 
pathway is upregulated in all BCCs, either by loss of 
function of Ptc1 (PTCH1 in humans) or gain of function 
mutations of Smo [12]. Gorlin’s syndrome, a condition 
in which patients develop hundreds of BCCs, is caused 
by PTCH1 haploinsufficiency, typically followed by 
subsequent somatic loss of heterozygosity (LOH) due to 
insults like UV irradiation [15]. The role of Hh signaling 
in SCCs is not well-defined, with only certain subsets 
displaying markers of Hh activation [16], though the 
Ptc1+/lacZ mouse model has shown increased susceptibility 
to UV-induced SCC formation [10]. This pattern of 
widespread upregulation of Hh signaling markers in BCCs 
and heterogeneous activation in SCCs is reminiscent of 
Dsg2. Interestingly, a number of cell signaling pathways 
regulated by Dsg2, including PI3K/Akt, MEK/Erk1/2 
and JAK/Stat3, can synergize with the Hh pathway to 
stimulate Gli transcriptional activity [11, 12]. Based on 
this evidence, we proposed to determine if Dsg2 and Hh 
signaling cooperate in skin tumor development.
To explore the interaction between Dsg2 and Hh 
signaling we crossed two established animal models: 
Ptc1+/lacZ and Inv-Dsg2 mice. Our Inv-Dsg2 transgenic 
animals, which overexpress Dsg2 in the suprabasal layers 
of the epidermis under control of the involucrin promoter 
[8], are an established model for Dsg2-mediated squamous 
tumor development. The Ptc1+/lacZ mice are heterozygous 
for Ptc1, with one copy replaced with a functional lacZ 
gene that serves as reporter of pathway activation, since 
Ptc1 is a Gli-target gene. Though generated as a mouse 
model for Gorlin syndrome; unlike humans, these mice 
only rarely develop spontaneous BCC [13] with advanced 
age, but require additional hits such as UV or γ-irradiation 
which can induce loss of p53 [14], or to be bred into a 
p53 null background to develop significant skin tumors 
[10]. Thus, the Ptc1+/lacZ mice serve primarily as reporters 
of Hh pathway activity, but are primed for skin tumor 
formation. Therefore, we crossed these two mouse models 
to determine if Dsg2 and Hh interact during chemical-
induced tumor development. Our results suggest a 
synergistic interaction between Dsg2 and Hh signaling in 
the development of both SCCs and BCCs.
RESULTS
Dsg2 enhances canonical Hh signaling in mouse 
skin and in cultured keratinocytes
To determine the effect of Dsg2 on Hh signaling 
in vivo, we quantified expression of gli1 and ptc1 mRNA 
in the skin of 6 week-old Inv-Dsg2 transgenic mice and 
wild type (WT) littermates. Analysis by qPCR confirmed 
enhanced Dsg2 expression and revealed an ~7-fold 
increase in gli1 and ptc1 mRNA in the skin of Inv-Dsg2 
mice (Figure 1A). As activation of the Hh pathway is a 
hallmark of hair follicles in anagen, we also normalized 
the gli1 and ptc1 Ct values to the anagen hair follicle 
marker sox9 to confirm that the increase in Hh target 
genes was not secondary to an increased number of 
anagen follicles. Strikingly, normalization of gli1 and 
ptc1 to sox9 resulted in an even higher upregulation of 
gli1 and ptc1 (~20 and 10-fold respectively) (Figure 1A); 
suggesting that the observed increase in gli1 and 
ptc1 could not be accounted for by an increase in hair 
follicle number or an alteration in the hair follicle cycle. 
Remarkably, expression of Shh at the transcript level was 
highly upregulated in the skin of Inv-Dsg2 mice (800-
fold vs. WT), suggesting that it may account for increased 
Gli target gene expression in vivo (Figure 1B). Thus, 
overexpressing Dsg2 in the epidermis increases canonical 
Hh pathway activity in vivo.
To obtain further proof that Dsg2 levels regulate 
activation of the canonical Hh pathway, we utilized 
SCC-derived A431 cells stably expressing control 
(A431+shGFP) or Dsg2 (A431+shDsg2) short hairpin 
RNA [21]. Stable knockdown of Dsg2 was accompanied 
by a striking reduction of Gli1 (Figure 1C), suggesting 
that Dsg2 might stimulate canonical Hh signaling. To test 
whether this holds true in non-tumorigenic keratinocytes, 
we compared expression the Hh target genes gli1 and 
ptc1 in HaCaT cells transfected with shRNA to GFP 
(HaCaT+shGFP) or Dsg2 (HaCaT+shDsg2). Because 
HaCaT cells express very low levels of Gli1, that are 
not detectable at the protein level, only qPCR was 
used. Knockdown of Dsg2 resulted in a significant 50% 
decrease in gli1 transcript levels compared to controls 
(Figure 1D). Altogether, these observations demonstrate 
that Dsg2 promotes canonical Hh signaling both in vitro 
and in vivo.
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Dsg2-mediated hyperproliferation is enhanced 
on the Ptc1+/lacZ background
To assess the biological consequence of the 
crosstalk between Dsg2 and Hh signaling, we bred 
our Inv-Dsg2 mice and the Ptc1+/lacZ reporter mice to 
generate Inv-Dsg2/Ptc1+/lacZ compound animals, single 
transgenic (Inv-Dsg2 and Ptc1+/LacZ) and WT littermates, 
which were born at the expected Mendelian rates. We 
measured epidermal thickness of the mice at different 
developmental stages (1–2 days, 6 weeks, and 3 months of 
age). Newborn mice appeared normal, with all genotypes 
exhibiting comparable epidermal thickness (Figure 2A). 
As we published before, by 6 weeks the Inv-Dsg2 mice 
showed signs of hyperplasia (Figure 2B). Strikingly, by 
3 months of age the Inv-Dsg2/Ptc1+/lacZ compound mice 
exhibited statistically significant increased hyperplasia 
compared to their Inv-Dsg2 counterparts, while there was 
no difference in average epidermal thickness between 
WT and Ptc1+/lacZ mice (Figure 2C), suggesting that a Ptc1 
haploinsufficiency allows for enhanced effects Dsg2 on 
skin homeostasis.
Next, we sought to determine if the increased 
hyperplasia resulted from defective terminal differentiation 
or enhanced proliferation. To assess significant defects on 
terminal differentiation, we analyzed the expression of 
cornified envelope markers. Immunofluorescent staining 
of loricrin revealed normal staining in the epidermis in 
all mice (Figure 2D). Additional cornified envelope 
markers, involucrin and filaggrin displayed similar 
results (data not shown), suggesting that the terminal 
differentiation proceeds relatively normally. While we 
cannot rule out more subtle effects on differentiation, this 
data suggests that impairment of terminal differentiation 
could not explain the enhanced skin hyperplasia of 
Dsg2/Ptc1+/lacZ mice. In contrast, BrdU incorporation 
revealed increased proliferation in the basal layer of the 
skin of Inv-Dsg2/Ptc1+/lacZ mice compared to Inv-Dsg2 
and Ptc1+/lacZ or WT animals (Figure 2E). These results 
indicate that Dsg2-mediated epidermal proliferation is 
enhanced on the Ptc1+/lacZ background, and suggests a 
possible synergistic effect of the two signaling pathways, 
as there is no change in Ptc1+/lacZ animals compared to 
wild-type.
Figure 1: Dsg2 enhances Gli1 expression. A-B. qPCR analysis of 6-week old backskin from Inv-Dsg2 (n = 8) and WT (n = 6) mice. 
Samples normalized to internal control (GAPDH); in addition to control for follicles in the anagen stage of development, samples were 
normalized to Sox9. C. Western analysis of A431-shDsg2 and A431-shDsg2 lysates (n = 3), for Dsg2 and Gli1. Actin serves as a loading 
control. Densitometry measurements were completed using image J. D. qPCR of HaCaT-shDsg2 and HaCaT-shGFP control cells (n = 3). 
Samples were normalized to GAPDH. All data are shown as the mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; t-test.
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Figure 2: Inv-Dsg2/Ptc1+/lacZ mice exhibit epidermal hyperproliferation. (A-C) Histological analysis of newborn mouse skin 
A. 6 weeks B. and 3-month C. mouse backskin. Epidermal thickness was measured as indicated by brackets. Graphical representation 
of average epidermal thickness is presented in microns. Newborn: WT (n = 3); Ptc1+/lacZ (n = 4); Inv-Dsg2 (n = 6); Inv-Dsg2/Ptc1+/lacZ 
(n = 4); 6 week: WT (n = 5); Ptc1+/lacZ (n = 2); Inv-Dsg2 (n = 5); Inv-Dsg2/Ptc1+/lacZ (n = 5); 3 month: WT (n = 10); Ptc1+/lacZ (n = 6);  
Inv-Dsg2 (n = 4); Inv-Dsg2/Ptc1+/lacZ (n = 7). D. IF of the cornified envelop marker loricrin (red); nuclei counterstained with DAPI (blue). 
E. Graphical representation of number of BrdU positive cells per 100 basal keratinocytes. WT (n = 5); Ptc1+/lacZ (n = 3); Inv-Dsg2 (n = 3); 
Inv-Dsg2/Ptc1+/lacZ (n = 4). The data are shown as the mean ± SEM. *p < 0.05; **p < 0.01; t-test. Scale bar = 50 microns.
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Hh signaling is activated in the interfollicular 
epidermis of Inv-Dsg2/ Ptc1+/lacZ mice
To investigate the origin of the phenotypic 
differences between the Inv-Dsg2 and Ptc1+/lacZ crossed 
progeny, we evaluated the expression of the Flag-tagged 
Dsg2 transgene and Hh pathway activity in the skin of 
all genotypes and control WT mice at three months 
of age. As expected, Dsg2.Flag expression was only 
detected by immunohistochemistry in Inv-Dsg2 and Inv-
Dsg2/Ptc1+/lacZ mice and was restricted to the suprabasal 
epidermis (Figure 3A). The X-gal staining which reports 
expression of Ptc1-lacZ, a marker of canonical Hh pathway 
activation, was detected only in mice harboring the lacZ 
reporter gene. Both Ptc1+/lacZ and Inv-Dsg2/Ptc1+/lacZ mice 
exhibited a comparable activation of the Hh pathway in 
the dermal papilla of hair follicles (Figure 3B). Differences 
between Ptc1+/lacZ and Inv-Dsg2/Ptc1+/lacZ animals emerged 
when the interfollicular epidermis (IFE) was examined. 
The IFE is typically void of detectable Hh pathway 
activity, and indeed Ptc1+/lacZ mice showed little to no 
X-gal staining outside of the hair follicles. Increased Hh 
reporter activity was observed in localized regions of the 
IFE of the Inv-Dsg2/Ptc1+/lacZ mice (Figure 3C), indicating 
that Dsg2 overexpression stimulates Hh signaling in 
keratinocytes in vivo.
Dsg2/Ptc1+/lacZ mice exhibit accelerated squamous 
tumor development
We previously demonstrated that the Inv-Dsg2 mice 
were more susceptible to chemical-induced squamous 
Figure 3: Inv-Dsg2/Ptc1+/lacZ mice exhibit interfollicular activation of the Hh pathway. A. IHC of mouse backskin with anti-
Flag antibodies detects Flag-tagged Dsg2 transgene expression (brown) in superficial epidermis, nuclei counterstained with hematoxylin. 
(B-C) X-Gal staining of mouse backskin depicting β-gal expression/Hh activity (blue) and counterstained with nuclear fast red, hair 
follicles which serve as positive controls B. and interfolicular epidermis C. Scale bar = 25 microns. Dashed line demarcates basement 
membrane zone.
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tumor development [7]. Since compound Inv-Dsg2/
Ptc1+/lacZ mice showed increased Hh signaling and 
hyperproliferation compared to Inv-Dsg2 animals, we 
investigated whether they are more susceptible to DMBA-
TPA induced tumor development. Mice were treated once 
with DMBA, followed by twice-weekly administrations of 
TPA for 26 weeks. All genotypes developed macroscopic 
lesions (Figure 4A) by 14 weeks of TPA treatment; 
however, tumors in the Inv-Dsg2/Ptc1+/lacZ mice emerged 
as early as 5 weeks of TPA treatment, and reached 100% 
incidence by week 9 (Figure 4C). In comparison, the other 
three genotypes developed tumors around week 7–8 of 
treatment and did not reach 100% incidence until weeks 
12–14 (Figure 4C). Thus, the Inv-Dsg2/Ptc1+/lacZ mice have 
accelerated macroscopic tumor formation compared to all 
other genotypes.
To determine if there were any differences in 
tumor load, we quantified the average size of tumors, 
the number of tumors per animal (tumor multiplicity) 
and the average tumor burden in all four genotypes. 
Tumor development in WT and Ptc1+/lacZ mice was highly 
comparable, suggesting no significant differences between 
the two genotypes throughout the duration of treatment. 
As we previously reported, mice overexpressing Dsg2 
developed more and larger tumors than WT mice. 
Comparison of Inv-Dsg2 Inv-Dsg2/Ptc1+/lacZ mice revealed 
no significant difference in tumor size (Figure 4D). 
However, Inv-Dsg2/Ptc1+/lacZ mice developed significantly 
more tumors than the Inv-Dsg2 counterparts during the 
early stages of development, weeks 7–13 (Figure 4E). 
Interestingly, after week 13 the difference in tumor 
number between Inv-Dsg2 and Inv-Dsg2/Ptc1+/lacZ mice 
leveled off. Similarly, average tumor burden, which 
takes into account tumor number and size, showed no 
difference between Inv-Dsg2 and Inv-Dsg2/Ptc1+/lacZ mice 
after week 13 (Figure 4F). Lack of difference in overall 
tumor burden but evidence of decreased tumor latency in 
response to chemical carcinogens in Inv-Dsg2/Ptc1+/lacZ 
mice, suggests a possible synergistic effect of the two 
pathways on the rate of tumor promotion.
We also compared the tumor morphology at the 
end of the treatment protocol. All genotypes developed 
histologically similar papillomas and in situ carcinomas 
(Figure 4B). None of the animals developed full-blown 
SCC or showed signs of metastasis. Surprisingly, yet 
in agreement with the similar burden and morphology, 
neither X-gal nor β-gal staining revealed activation 
of the Hh pathway in squamous tumors of Ptc1+/lacZ 
or Inv-Dsg2/Ptc1+/lacZ mice (Figure 5). However we 
detected strong X-gal staining in the dermis underlying 
the tumors in Inv-Dsg2/Ptc1+/lacZ mice, which was not 
observed in Ptc1+/lacZ animals (Figure 5A). β-gal staining 
further confirmed the activation of the Hh pathway in the 
dermal fibroblasts of the compound mice (Figure 5B). 
We also found an increased expression of Shh by 
immunohistochemical (IHC) staining in the dermis, but 
not in the epidermis, of Dsg2 transgenic mice, which 
explains the X-gal and β-gal staining of dermal fibroblasts 
(Figure 5C). It is therefore possible that activation of the 
Hh pathway in the dermis in a Shh-dependent manner 
could account for the earlier tumor emergence in the 
Inv-Dsg2/Ptc1+/lacZ mice. Finally, to determine if there 
is a change in growth and survival signaling in the SCC 
tumors of all genotypes, we stained for phosphorylated 
Erk1/2. Interestingly, while tumors of all genotypes exhibit 
some level of staining, total phosphorylation and nuclear 
localization were more prominent in the Inv-Dsg2/Ptc1+/lacZ 
mice than in any other genotype (Figure 6), as confirmed 
by confirmed by four independent blind observers.
Dsg2 enhances BCC formation in Ptc1 
heterozygote animals
Remarkably, while performing the pathology 
analysis, we unexpectedly observed BCC tumor 
development in response to DMBA-TPA in Ptc1+/lacZ and 
Dsg2/Ptc1+/lacZ mice but not in WT or Inv-Dsg2 animals. 
BCCs in both Ptc1+/lacZ and Inv-Dsg2/Ptc1+/lacZ mice had a 
similar morphology (Figure 7A) and exhibited classical 
activation of the Hh pathway, as determined by strong 
X-gal staining (Figure 7A). IHC staining of nuclear 
β-gal further confirmed pathway activation in the BCCs 
(Figure 7B). Importantly, the BCC tumor burden was 
~2 fold larger in Inv-Dsg2/Ptc1+/lacZ compound animals 
compared to Ptc1+/lacZ mice (Figure 7C), suggesting that 
the presence of Dsg2 enhances BCC development in the 
Ptc1 heterozygote background.
DISCUSSION
Emerging evidence supports the existence of 
non-adhesive functions of Dsg2. We and others have 
shown that Dsg2 promotes keratinocytes proliferation 
and tumor development by activation of mitogenic 
signaling pathways [7, 9]. This work expands on our 
previous findings that established a role for Dsg2 in skin 
carcinogenesis, by identifying an unrecognized function 
for Dsg2 in enhancing canonical Hh signaling.
In the present study we demonstrate the existence of 
a generalized crosstalk between Dsg2 and Hh signaling in 
different cell types that promotes epidermal proliferation, 
accelerates squamous-derived tumorigenesis, and 
enhances BCC development in vivo. Our findings suggest 
that Dsg2 or its downstream signaling, which is not fully 
understood, might constitute potential new targets for 
intervention in squamous and basal cell-derived lesions.
Using compound Inv-Dsg2/Ptc1+/lacZ mice, which 
overexpress Dsg2 in the suprabasal epidermis and are 
heterozygous for Ptc1, we showed a remarkable synergism 
in the promotion of epidermal hyperproliferation and 
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Figure 4: DMBA-TPA treatment results in accelerated growth of squamous derived neoplasia in Inv-Dsg2/Ptc1+/LacZ 
mice. A. Macroscopic tumor formation is observed in all mice after DMBA-TPA treatment. B. Histological analysis reveals papillomas 
and in situ carcinomas in all genotypes (scale bars = 100 and 250 microns, respectively). C. Tumor incidence is depicted as percentage 
of mice exhibiting tumors. D. The average tumor diameter was determined for all mice. E. Tumor multiplicity represents the average 
number of tumors per genotype. F. Tumor burden, accounts for size and number of tumors, is represented as the sum of tumors x size (Σ). 
WT (n = 11); Ptc1+/lacZ (n = 5); Inv-Dsg2 (n = 10); Inv-Dsg2/Ptc1+/lacZ (n = 8). The data are shown as the mean ± SEM. *p < 0.05; 
**p < 0.01; t-test.
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upregulation of the canonical Hh pathway in some 
regions of the IFE compared to the Ptc1+/lacZ genotype. 
We hypothesize that these IFE regions with enhanced Hh 
activity may expand to form either spontaneous or DMBA-
TPA induced BCC. BCC can arise in Ptc1 heterozygous 
mice either through LOH of the WT Ptc1 allele [10] 
or through activation of the pathway via other means. 
For instance Ptc1+/– mice crossed with mice Sufu+/–, 
a negative regulator of the Hh pathway downstream of 
Smo, increased basaloid epidermal proliferations [16]. 
Additionally, Ptc1+/lacZ mice with loss of p53 function 
are also more prone to spontaneous BCC formation [17]. 
Thus, we speculate that the normally effective regulation 
of the Hh pathway by just a single allele of Ptc1 is 
overcome, potentially through the inhibition of the 
function of that single copy of Ptc1 via ligand binding and/
or by downstream synergism with other Dsg2-mediated 
signaling. Furthermore, we observe spontaneous early 
BCC development only in Inv-Dsg2/Ptc1+/lacZ mice 
(unpublished observations). While Ptc1+/lacZ mice can 
develop spontaneous BCCs, they are rare and occur only 
at more advanced ages. We also note that BCCs are not 
reported in WT or Inv-Dsg2 mice, even at advanced ages.
Overexpression of Dsg2 in the Ptc1 heterozygous 
background also leads to accelerated squamous tumor 
development in response to DMBA/TPA treatment; 
however, this effect is only observed during early tumor 
development. This suggests that Dsg2-Hh crosstalk 
can enhance tumor promotion, but that it is most likely 
dispensable for Dsg2-mediated cutaneous tumor 
development and progression. Indeed, this corroborates 
the human tissue array studies showing that Hh signaling 
is not required for cutaneous SCC development, but 
increased Shh expression is associated with decreased 
survival in oral SCC [18].
Interestingly, while Ptc1+/lacZ mice were also shown 
to be more prone to SCC development in response to UV-
irradiation compared to WT mice, those lesions were also 
negative for Gli1 and canonical pathway activation [10]. 
We did not observe a similar increase in response to 
Figure 5: Inv-Dsg2/Ptc1+/lacZ mice display Hh activity in the tumor stroma. A. Consecutive sections of papillomas reveal 
the tumor epithelium is negative for X-gal, but tumor stroma of the Inv-Dsg2/Ptc1+/lacZ mice positively stained for Hh activation (blue). 
B. β-gal IHC confirms activation of the Hh pathway in fibroblasts of the tumor stroma. C. IHC staining reveals Shh in the SCC tumor 
stroma. Dashed line demarcates basement membrane zone. Scale bar = 100 microns, 50 microns for insets.
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DMBA-TPA treatment, which typically occurs as a 
result of Ras mutations [19]. This may suggest differing 
mechanisms for squamous tumor development, and 
possibly a non-canonical role for Ptc1 in UV-mediated 
tumorigenesis.
Surprisingly in our Inv-Dsg2/Ptc1+/lacZ mice, the 
activation of the Hh pathway is not observed in SCC 
tumors, but rather in the dermis underlying the tumors. We 
also observed an increase in Shh localized to the dermis, 
which may explain the increase canonical Hh pathway 
activation in these dermal fibroblasts. Hh activation has 
been reported in the stroma of various tumors [20, 21] and 
mounting evidence suggests that the stroma plays vital 
roles in tumor promotion, maintenance, and progression 
[22]. We propose that the activation of Hh signaling in the 
dermis facilitates a tumor microenvironment conducive to 
accelerated growth, similar to recent studies in prostate 
and pancreatic cancers [23, 24]. Therefore, we hypothesize 
Figure 6: Inv-Dsg2/Ptc1+/lacZ squamous lesions exhibit enhanced activation of Phospho-Erk1/2. IHC of Phospho-Erk1/2 
reveals increased nuclear localization within the Inv-Dsg2/Ptc1+/lacZ squamous lesions. Note that signal is not observed in BCC. Scale 
bar = 100 microns, 50 microns for insets. Scale bar = 100 microns.
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that Dsg2-mediated squamous tumor promotion may 
be accelerated by the activation of Hh signaling in the 
adjacent dermis. Indeed, increased activation of Erk1/2 
suggests enhanced growth and survival signaling activity 
in Inv-Dsg2/Ptc1+/lacZ tumors.
Finally, another potential driver of Dsg2-Hh 
tumorigenesis is activation of non-canonical Hh signaling 
[25, 26]. While this study was designed to analyze 
canonical, Gli-dependent Hh signaling, Ptc1 and Smo 
exert other functions independent of transcription that 
regulate cell survival. In particular, Ptc1 is an inducer of 
apoptosis, and inhibition of its function by Dsg2 could 
increase cell survival and tumor formation [27]. Future 
investigations are needed to determine what role Dsg2 
may have in activating non-canonical Hh signaling, its 
role on keratinocyte proliferation and survival.
To our knowledge, this is the first report that a 
desmosomal cadherin can facilitate activation of the 
Hh signaling pathway and promote BCC and SCC 
tumor formation. The significance of Dsg2-Hh crosstalk 
has implications beyond cutaneous tumors, as both players 
are deregulated in a variety of cancers including oral head 
and neck SCC, gastric, and prostate cancers [24, 26, 
28–32]. Moreover, our data specifically suggests that two 
distinct mechanisms of Dsg2-Hh synergy are responsible 
for the effects on the different tumor types. DMBA/TPA-
induced BCCs in Inv-Dsg2/Ptc1+/lacZ mice exhibit classical 
activation of the Hh pathway; whereas, squamous-derived 
neoplasia lack detectable Hh activity. Furthermore, 
unlike BCCs, squamous lesions are accompanied by Shh 
expression and Hh pathway activity in the underlying 
dermis, and the tumors themselves harbor increased 
levels of activated Erk1/2. Future studies to elucidate these 
differing mechanisms of Hh pathway induction in response 
to Dsg2 are underway. The implication of the crosstalk 
in various tumors has the potential to identify targets for 
novel and tailored cancer treatments. Furthermore, these 
findings may be relevant to the current therapeutic options 
Figure 7: DMBA-TPA induces enhanced BCC formation in Inv-Dsg2/Ptc1+/LacZ mice. A. Microscopic BCC formation is 
observed in all mice harboring the Ptc1+/lacZ gene (H&E), and these tumors display characteristic activation of the Hh pathway (X-gal). BCCs 
were not found in any WT or Inv-Dsg2 mice. B. β-gal IHC confirms activation of the Hh pathway in the induced BCCs. Scale bars = 100 
microns. C. BCC tumor burden is increased more than two-fold in Inv-Dsg2/Ptc1+/LacZ mice. Ptc1+/lacZ (n = 4); Inv-Dsg2/Ptc1+/lacZ (n = 6). 
The data are shown as the mean ± SEM. **p < 0.01; t-test.
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for squamous lesions, as they suggest that the canonical 
Hh pathway active in the dermis adjacent to those tumors 
has a positive influence in tumor promotion, and could be 
suggestive of an additional route of intervention using the 
FDA approved Smo inhibitor Vismodegib.
MATERIALS AND METHODS
Ethics statement
Investigation using animals has been conducted in 
accordance with the ethical standards according to national 
and international guidelines and has been approved by 
the authors’ Institutional Animal Care & Use Committee 
approvals.
Cell culture
All reagents were from Sigma (St. Louis, MO) or 
Fisher (Waltham, MA) unless otherwise indicated. A431-
shDsg2, A431-shGFP, HaCaT-shDsg2, and HaCaT-shGFP 
cells were previously established (Gift from Dr. James 
K. Wahl III, University of Nebraska, [15]. Cells were 
grown to ~70% confluency in complete DMEM with 10% 
FBS (Gemini Bio Products, West Sacramento, CA) and 
then serum starved (0.5% FBS) for 24–48 hours prior to 
lysis in Triton X-100 lysis buffer for Western analysis.
Western analysis
Proteins were resolved over 5–10% SDS-PAGE 
(Bio-Rad Laboratories), transferred to PVDF membrane, 
non-specific sites blocked in 5% Carnation milk in PBS/
Tween-20 and incubated in primary antibodies in 1% BSA 
in PBS/T-20 overnight at 4°C. Membranes were washed 
and incubated with HRP-conjugated secondary antibodies 
from Jackson Immunoresearch (West Grove, PA) and 
signal was detected with chemiluminescence (ECL, GE 
Life Sciences, Piscataway, NJ). Antibodies: 10D2 (1:100; 
gift from Dr. Wahl), Actin (1:100, 000; Calbiochem; 
Billerica, MA), Gli1 (1:1000; Cell Signaling Technology, 
Danvers, MA). Quantitation performed using ImageJ 
available at http://rsb.info.nih.gov/ij; developed by Wayne 
Rasband (National Institutes of Health, Bethesda, MD).
RNA-extraction and RT-qPCR
RNA was extracted from cultured cells or skin 
tissues using RNAeasy kit (Qiagen; Valencia, CA) or 
Trizol (Life Technologies, Carlsbad, CA), respectively. 
DNA was removed using TURBO DNase I (Life 
Technologies) and cDNA was generated using High-
Capacity cDNA Reverse Transcription Kit (Life 
Technologies). qPCR was performed on BioRad 
MiniOpticon with Sso Eva Green (Bio-Rad, Hercules, 
CA). Forward (F) and reverse (R) primers are as follows. 
Mouse – Dsg2-F: GAGGAATTGAGTGCAGCACATAC, 
Dsg2-R: CTTGCTTCCACCGTCAAGG;
Gli1-F: GTCCGCGCCTCTCCCACATACTA,
Gli1-R: ACGCTCGCAGGGCAGGGATAG;
Ptc1-F: GGAAGGGGCAAAGCTACAGT,
Ptc1-R: TCCACCGTAAAGGAGGCT TA;
Sox9-F: TCGGTGAAGAACGGACAAGC,
Sox9-R: TGAGATTGCCCAGAGTGCTCG;
Gapdh-F: CCCATCACCATCTTCCAGGAGCGA;
Gapdh-R: TCCACCCTTCAAGTGGCCC.
Human – DSG2-F: GAAGAGTTGAGTGCAGCACATAC, 
DSG2-R: CTTGCTTCTACTGTCAAAGTCTACG;
GLI1-F: CCAACTCCACAGGCATACAGGATCCC,
GLI1-R: TCTTGGGAGTCAAATTCCTGGCTGCA;
GAPDH-F: CCCATCACCATCTTCCAGGAGCGA,
GAPDH-R: CCCCCTGCAAATGAGCCCCAG.
Transgenic and knock-in mouse models
All animal studies were in compliance with the 
Institutional Animal Care & Use Committee approvals. 
Ptc1+/LacZ knock-in reporter mice (Ptch1tm1Mps/J) were 
obtained from Jackson Labs (Bar Harbor, ME). Inv-Dsg2 
mice were previously generated and described in detail 
[7]. All animals were maintained under ALAAC approved 
conditions. Ptc1+/LacZ and Inv-Dsg2 mice were crossed 
to yield WT, Ptc1+/LacZ Inv-Dsg2 and Inv-Dsg2/Ptc1+/LacZ 
mice. Animals were sacrificed at indicated time points and 
tissues collected for analysis.
DMBA-TPA skin carcinogenesis
DMBA (7,12-dimethylbenz[a]anthracene; 400 nmol 
in 200 μl acetone) was applied directly to shaved backskin 
of 6–8 week old mice under red light, and housed overnight 
in the dark. Subsequently, mice were treated topically, 
twice weekly with TPA (12-O-tetradecanoylphorbol 
13-acetate; 17 nmol in 200 μl acetone) for 26 weeks. 
Tumors were counted and measured weekly. After 
26 weeks mice were sacrificed and tumors collected for 
analysis.
Histology, microscopy, and morphometric 
analysis
Tissues were fixed in 10% formalin, paraffin 
embedded, processed for histology with Hematoxylin 
and Eosin. Bright field images were acquired with 
either EVOS microscope system (Life Technologies, 
Carlsbad, CA) or Zeiss Axioshop microscope (Carl Zeiss 
Microscopy, Thornwood, NY) with SPOT Insight camera 
and software (HiTech Instruments, Pennsburg, PA). 
Epidermal measurements were performed using EVOS 
software. BCCs were identified in H&E sections by the 
following characteristics: discrete, nodular aggregations 
of hyperchromatic epithelial basaloid cells with prominent 
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nuclei and scant cytoplasm; tumor area measurements 
were completed using ImageJ.
BrdU incorporation assay
Mice were injected subcutaneously in the dorsal 
region with 5-bromo-2-deoxyuridine (50 mg/gram). After 
one hour, mice were sacrificed and tissue collected for 
processing. Direct immunofluorescence was performed 
using Anti-BrdU-FITC (BD Biosciences, San Jose, CA). 
A percentage of BrdU-positive over total epidermal basal 
cells was reported.
LacZ reporter gene detection
Tissues were fixed in 4% paraformaldehyde for 
20–40 minutes at room temperature and incubated 
overnight in 1 mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-
beta-D-galacto-pyranoside) at 37°C. Tissues were then 
processed for OCT or histology, and counterstained with 
Nuclear Fast Red (Rowley Biochemical, Danvers, MA).
Immunofluorescence (IF) and 
immunohistochemistry (IHC)
Immunostaining was performed on formalin-fixed 
paraffin embedded sections as previously described [6]. 
IF utilized Alexa-Flour secondary antibodies (Life 
Technologies) with DAPI (100 ng/ml) for DNA 
counterstaining. IHC was completed with EnVision HRP 
antibody system (Dako, Carpinteria, CA). Antibodies: anti-
FLAG pAb, 1:1000 (Sigma); anti-loricrin mAb, 1:1000 
(Covance); anti-β-gal pAb 1:5000 (MP Biomedicals, 
Santa Ana, CA); 5E1 anti-Shh mAb 1:50 (DSHB, Iowa 
City, IA); anti-Phospho-Erk1/2 1:400 (Cell Signaling, 
Danvers, MA).
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